Type I and III collagen degradation products in serum predict patient survival in head and neck squamous cell carcinoma

Oral Oncology

Volumn 48, Issue 2, 2012, Pages 136-140

  Nurmenniemi, Sini ^a   Koivula, Marja Kaisa ^a,b   Nyberg, Pia ^a   Tervahartiala, Taina ^c   Sorsa, Timo ^c   Mattila, Petri S ^c   Salo, Tuula ^a   Risteli, Juha ^a  

^a UNIVERSITY OF OULU   (Finland)

^b KAINUU CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Head and neck cancer; MMP 8; Prognosis; Survival; TIMP 1; Type I collagen; Type III collagen

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; COLLAGEN TYPE 3 N TERMINAL TELOPEPTIDE; METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEASE 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLLAGEN DEGRADATION; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL ASSAY; CARCINOMA, SQUAMOUS CELL; COLLAGEN TYPE I; COLLAGEN TYPE III; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MATRIX METALLOPROTEINASE 8; MIDDLE AGED; PEPTIDES; PROGNOSIS; SURVIVAL RATE; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84856364938     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2011.09.002     Document Type: Article

References (34)

1. R. Kalluri, and M. Zeisberg Fibroblasts in cancer Nat Rev Cancer 6 5 2006 392 401
2. T.D. Tlsty, and L.M. Coussens Tumor stroma and regulation of cancer development Annu Rev Pathol 1 2006 119 150
3. R. Kalluri EMT: when epithelial cells decide to become mesenchymal-like cells J Clin Invest 119 6 2009 1417 1419
4. M. Egeblad, M.G. Rasch, and V.M. Weaver Dynamic interplay between the collagen scaffold and tumor evolution Curr Opin Cell Biol 22 5 2010 697 706
5. S. Kauppila, M.K. Bode, F. Stenbäck, L. Risteli, and J. Risteli Cross-linked telopeptides of type I and III collagens in malignant ovarian tumours in vivo Br J Cancer 81 4 1999 654 661 (Pubitemid 29458861)
6. M.K. Bode, M. Mosorin, J. Satta, L. Risteli, T. Juvonen, and J. Risteli Complete processing of type III collagen in atherosclerotic plaques Arterioscler Thromb Vasc Biol 19 6 1999 1506 1511 (Pubitemid 29263021)
7. T. Jussila, S. Kauppila, M. Bode, J. Tapanainen, J. Risteli, and L. Risteli Synthesis and maturation of type I and type III collagens in endometrial adenocarcinoma Eur J Obstet Gynecol Reprod Biol 115 1 2004 66 74 (Pubitemid 38844221)
8. M.K. Bode, T.J. Karttunen, J. Mäkelä, L. Risteli, and J. Risteli Type I and III collagens in human colon cancer and diverticulosis Scand J Gastroenterol 35 7 2000 747 752 (Pubitemid 30637253)
9. J. Risteli, I. Elomaa, S. Niemi, A. Novamo, and L. Risteli Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation Clin Chem 39 4 1993 635 640 (Pubitemid 23118314)
10. K. Yoshida, S. Sumi, K. Arai, F. Koga, H. Umeda, and Y. Hosoya Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma Cancer 80 9 1997 1760 1767 (Pubitemid 27475934)
11. M. Noguchi, and S. Noda Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer J Urol 166 3 2001 1106 1110 (Pubitemid 32751053)
12. A. Kataoka, T. Yuasa, S. Kageyama, N. Tsuchiya, T. Habuchi, and H. Iwaki Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen Clin Oncol (R Coll Radiol) 18 6 2006 480 484 (Pubitemid 43942228)
13. N. Voorzanger-Rousselot, F. Juillet, E. Mareau, J. Zimmermann, T. Kalebic, and P. Garnero Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crosssectional and longitudinal evaluation Br J Cancer 95 4 2006 506 514 (Pubitemid 44232560)
14. N. Abildgaard, K. Brixen, J.E. Kristensen, E.F. Eriksen, J.L. Nielsen, and L. Heickendorff Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-ntx are predictive for early progression of the bone disease during standard chemotherapy Br J Haematol 120 2 2003 235 242 (Pubitemid 36194171)
15. U. Heider, C. Fleissner, I. Zavrski, M. Kaiser, M. Hecht, and C. Jakob Bone markers in multiple myeloma Eur J Cancer 42 11 2006 1544 1553 (Pubitemid 44118764)
16. A. Aruga, M. Koizumi, R. Hotta, S. Takahashi, and E. Ogata Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer Br J Cancer 76 6 1997 760 764 (Pubitemid 27379743)
17. S. Ylisirniö, M.L. Sassi, J. Risteli, T. Turpeenniemi-Hujanen, and A. Jukkola Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer Anticancer Res 19 6C 1999 5577 5581 (Pubitemid 30093331)
18. S. Ylisirniö, M. Höyhtyä, R. Mäkitaro, P. Pääkkö, J. Risteli, and V.L. Kinnula Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer Clin Cancer Res 7 6 2001 1633 1637 (Pubitemid 32708629)
19. A. Ramankulov, M. Lein, G. Kristiansen, S.A. Loening, and K. Jung Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer Prostate 67 3 2007 330 340
20. Y. Nabeya, H. Shimada, S. Okazumi, H. Matsubara, Y. Gunji, and T. Suzuki Serum cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as a prognostic tumor marker in patients with esophageal squamous cell carcinoma Cancer 94 4 2002 940 949 (Pubitemid 34150848)
21. M. Santala, L. Risteli, U. Puistola, J. Risteli, and A. Kauppila Elevated serum ICTP concentrations reflect poor prognosis in patients with ovarian carcinoma Ann Med 27 1 1995 57 61
22. M. Santala, M. Simojoki, J. Risteli, L. Risteli, and A. Kauppila Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer Clin Cancer Res 5 12 1999 4091 4096 (Pubitemid 30013790)
23. R. Keskikuru, R. Bloigu, J. Risteli, V. Kataja, and A. Jukkola Elevated preoperative serum ICTP is a prognostic factor for overall and disease-free survival in breast cancer Oncol Rep 9 6 2002 1323 1327
24. E. Terpos, M.A. Dimopoulos, O. Sezer, D. Roodman, N. Abildgaard, and R. Vescio The use of biochemical markers of bone remodeling in multiple myeloma: a report of the international myeloma working group Leukemia 24 10 2010 1700 1712
25. J.T. Korpi, V. Kervinen, H. Mäklin, A. Väänänen, M. Lahtinen, and E. Läärä Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer Br J Cancer 98 4 2008 766 775 (Pubitemid 351272624)
26. P. Pradhan-Palikhe, T. Vesterinen, J. Tarkkanen, I. Leivo, T. Sorsa, and T. Salo Plasma level of tissue inhibitor of matrix metalloproteinase-1 but not that of matrix metalloproteinase-8 predicts survival in head and neck squamous cell cancer Oral Oncol 46 7 2010 514 518
27. A.M. Tuomainen, K. Nyyssönen, J.A. Laukkanen, T. Tervahartiala, T.P. Tuomainen, and J.T. Salonen Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men Arterioscler Thromb Vasc Biol 27 12 2007 2722 2728 (Pubitemid 350158928)
28. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. 2008. ISBN 3-900051-07-0, URL http://www.R-project.org.
29. N. Barascuk, S.S. Veidal, L. Larsen, D.V. Larsen, M.R. Larsen, and J. Wang A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen Clin Biochem 43 10-11 2010 899 904
30. E. Vassiliadis, S.S. Veidal, N. Barascuk, J.B. Mullick, R.E. Clausen, and L. Larsen Measurement of matrix metalloproteinase 9-mediated collagen type III degradation fragment as a marker of skin fibrosis BMC Dermatol 11 1 2011 6
31. S. Chakraborti, M. Mandal, S. Das, A. Mandal, and T. Chakraborti Regulation of matrix metalloproteinases: an overview Mol Cell Biochem 253 1-2 2003 269 285
32. T. Hayakawa, K. Yamashita, K. Tanzawa, E. Uchijima, and K. Iwata Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum FEBS Lett 298 1 1992 29 32
33. R. Chirco, X.W. Liu, K.K. Jung, and H.R. Kim Novel functions of TIMPs in cell signaling Cancer Metastasis Rev 25 1 2006 99 113 (Pubitemid 43723986)
34. W.G. Stetler-Stevenson Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities Sci Signal 1 27 2008 re6